BTK and diffuse large B-cell lymphoma: Overexpression of transcription factor EGR1 resulting in metabolic reprogramming to oxidative phosphorylation (OXPHOS) has also been recently implicated in BTK-inhibitor resistance in MCL and ABC subtype of DLBCL (15).